LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.

This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...